Sinovac Biotech (NASDAQ: SVA) reported a significant swing to losses in its first-half results, with earnings per share falling to $(0.84) from $0.06 in the corresponding period last year. This represents a 1500 percent decrease in profitability metrics on a per-share basis.

Despite the deterioration in bottom-line figures, the company demonstrated growth in its top line. Sinovac logged sales of $147.079 million for the half, up 12.90 percent from $130.270 million recorded during the same timeframe in the prior fiscal year.

Financial Performance Overview

The divergence between revenue growth and earnings decline highlights a compression in profitability despite higher sales volumes. The following table outlines the key financial metrics for the period:

What the Numbers Show

While revenue expanded by nearly 13 percent, the company’s ability to convert that top-line growth into shareholder value deteriorated sharply. The shift from a positive EPS of $0.06 to a negative $(0.84) indicates that operating costs or other expenses rose at a significantly faster rate than revenue, eroding the margin entirely and resulting in a net loss position for the half.

Sinovac Biotech Ltd. has regained compliance with the Nasdaq Global Market's listing requirements following the submission of its delayed annual report. The company received a notification letter dated June 10, 2026, from a Hearing Advisor at The Nasdaq Stock Market LLC confirming the compliance with Listing Rule 5250(c)(1). This development resolves the immediate risk of delisting for the China-based biopharmaceutical firm.

The compliance determination by the Hearings Panel on May 20, 2026, confirmed that Sinovac met the necessary standards. Consequently, the hearing requested by the company has been canceled. However, the company will continue to operate under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027, ensuring continued adherence to market regulations.

Sinovac had faced potential non-compliance due to delays in financial reporting. The company filed its annual report on Form 20-F for the year ended December 31, 2025, on June 5, 2026. This filing addressed the specific deficiencies cited by the exchange and restored the company's standing.

Sinovac Biotech Ltd. specializes in the research, development, manufacturing, and commercialization of vaccines. The company's portfolio includes vaccines for influenza, viral hepatitis, and pneumococcal disease, among others. Notably, three of its vaccines have been prequalified by the World Health Organization (WHO).